Pentamethylpyrromethene boron difluoride complexes in human ovarian cancer photodynamic therapy

Lee Roy Morgan; Aulena Chaudhuri; Laura E. Gillen; Joseph H. Boyer; Lionel T. Wolford

doi:10.1117/12.17671

1 July 1990 Pentamethylpyrromethene boron difluoride complexes in human ovarian cancer photodynamic therapy

Lee Roy Morgan, Aulena Chaudhuri, Laura E. Gillen, Joseph H. Boyer, Lionel T. Wolford

Proceedings Volume 1203, Photodynamic Therapy: Mechanisms II; (1990) https://doi.org/10.1117/12.17671
Event: OE/LASE '90, 1990, Los Angeles, CA, United States

Abstract

Quasiaromatic heterocycles (QAM) such as substituted 1 , 3 , 5 , 7 , 8-pentamethylpyrromethene boron difluorides (PMP-BF2) and - (dimethoxyphosphinylmethyl, methyl) bimane have been evaluated for their abilities to produce cellular toxicities when used in photodynamic therapy (PDT) for ovarian cancer. The most active QAH tested to date has been the disodiuxn salt of PMP-2,6-disulfonate--BF2 (PMPDS-BF2). Human ovarian cancer cells from fifteen different patients have been grown in culture. Cells were obtained from biopsy material and grown in RPMI medium with 10% FBA plus penicillin and streptomycin. Cells were harvested and as single cell suspensions exposed to PMP-BF2 complexes or bimanes in concentrations of 0.004-0.4 ug/106 cells/ml of medium. Initially the cells were exposed to the chemicals for 30 minutes in a 5% CO2 incubator (37°C) with gentle shaking. The cells were washed with plain RPMI medium, then resuspended in the enriched RPMI medium and exposed to a sunlamp for 10-20 minutes. Cells were then allowed to grow in an soft agar culture media at 37°C (5% C02) for 14 days. When compared to controls (only light or only chemicals) there was 100% inhibition of all cellular growth for PMPDSBF2 at the 0.4 ug/mi concentrations. There was variations in concentrations of the chemical needed to produce 100% inhibition when the 15 different ovarian cancer cell specimens were compared at all concentrations. PMP-BF2 complexes are characterized by extremely high extinction coefficients, superior laser activity and little if any triplet-triplet absorption. The biamanes share these properties however are less active in ovarian cancer cell The lasing properties of PMP-BF2, and bimanes will be compared to their PDT effectiveness.

Citation Download Citation

Lee Roy Morgan, Aulena Chaudhuri, Laura E. Gillen, Joseph H. Boyer, and Lionel T. Wolford "Pentamethylpyrromethene boron difluoride complexes in human ovarian cancer photodynamic therapy", Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); https://doi.org/10.1117/12.17671

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available